Phase I and pharmacokinetic study of KRN5500, a spicamycin derivative, for patients with advanced solid tumors

Japanese Journal of Clinical Oncology

Volumn 33, Issue 6, 2003, Pages 302-308

  Yamamoto, Noboru ^a   Tamura, Tomohide ^a   Kamiya, Yoshikazu ^a   Ono, Hiroyuki ^a   Kondoh, Hitoshi ^a   Shirao, Kuniaki ^a   Matsumura, Yasuhiro ^a   Tanigawara, Yusuke ^b   Shimada, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Fatigue; KRN5500; Phase I study; Protein synthesis inhibitor; Pulmonary toxicity

Indexed keywords

6 [4 DEOXY 4 (2,4 TETRADECADIENOYLGLYCYLAMINO) GLYCERO BETA MANNOHEPTOPYRANOSYLAMINO] 9H PURINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; SPICAMYCIN; PROTEIN SYNTHESIS INHIBITOR; PURINE NUCLEOSIDE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COLON CANCER; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FATIGUE; FEMALE; HUMAN; HYPERBILIRUBINEMIA; INTERSTITIAL PNEUMONIA; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; PHASE 1 CLINICAL TRIAL; PROTHROMBIN TIME; SOLID TUMOR; STOMACH CANCER; TOXICITY TESTING; VOMITING; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG EFFECT; INTRAVENOUS DRUG ADMINISTRATION; LUNG; METABOLISM; MIDDLE AGED; NEOPLASM;

ADULT; AGED; AREA UNDER CURVE; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NAUSEA; NEOPLASMS; PROTEIN SYNTHESIS INHIBITORS; PURINE NUCLEOSIDES; VOMITING, ANTICIPATORY;

EID: 0042284740     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyg051     Document Type: Article

References (15)

1. Hayakawa Y, Nakagawa M, Kawai H, Tanabe K, Nakayama H, Shimazu A, et al. Studies on the differentiation inducers of myeloid leukemic cells. III. Spicamycin, a new inducer of differentiation of HL-60 human promyelocytic leukemia cells. J Antibiot 1983;36:934-7.
2. Hayakawa Y, Nakagawa M, Kawai H, Tanabe K, Nakayama H, Shimazu A, et al. Spicamycin, a new differentiation inducer of mouse myeloid leukemia cells (M1) and human promyelocytic leukemia cells (HL-60). Agric Biol Chem 1985;49:2685-91.
3. Kamishohara M, Kawai H, Odagawa A, Isoe T, Mochizuki J, Uchida T, et al. Structure-antitumor activity relationship of semi-synthetic spicamycin analogues. J Antibiot 1993;46:1439-46.
4. Kamishohara M, Kawai H, Sakai T, Isoe T, Hasegawa K, Moebizuki J, et al. Antitumor activity of a spicamycin derivative, KRN5500 and its active metabolite in tumor cells. Oncol Res 1994;6:383-90.
5. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No 40. Geneva: World Health Organization 1979.
6. Schneiderman MA. Mouse to man: Statistical problems in bringing a drug to clinical trial. In: Proceedings of the 5th Berkeley Symposium on Mathematical Statistics Problems, University California, vol. 4. 1967;855-66.
7. Yoshioka E, Morino M, Tanaka H, Shinkai H. Manual and automatic extraction and high-performance liquid chromatographic determination of a spicamycin derivative, KRN5500, in rat plasma. J Chromatogr B 1997; 691:371-5.
8. Eder JP, Supko JG, Ryan K, Roper N, Kinchla DP, Kufe DW, et al. A phase I study of the spicamycin analogue KRN5500. Proc Am Assoc Cancer Res 1999;40:604 (abstr.).
9. Weiss RB, Muggia FM. Cytotoxic drug-induced pulmonary disease: Update 1980. Am J Med 1980;68:259-66.
10. Collis CH. Lung damage from cytotoxic drugs. Cancer Chemother Pharmacol 1980;4:17-27.
11. Orwoll ES, Kiessling, PJ, Patterson JR. Interstitial pneumonia from mitomycin. Ann Intern Med 1978;89:352-5.
12. Catimel G, Coquard R, Guastalla JP, Merrouche Y, La Bail N, Alakl MK, et al. Phase I study of RP 49532A, a new protein-synthesis inhibitor, in patients with advanced refractory solid tumors. Cancer Chemother Pharmacol 1995;35:246-8.
13. Murphy WK, Burgess MA, Valdivieso M, Livingston RB, Bodey GP, Freireich EJ. Phase I clinical evaluation of anguidine. Cancer Treat Rep 1978;62:1497-502.
14. Lee YS, Nishio K, Ogasawara H, Funayama Y, Ohira T, Saijo N. In vitro cytotoxicity of a novel antitumour antibiotic, spicamycin derivative, in human lung cancer cell lines. Cancer Res 1995;55:1075-9.
15. Matsumura Y, Yokoyama M, Kataoka K, Okano T, Sakurai Y, Kawaguchi T, et al. Reduction of the side effects of an antitumor agent, KRN5500, by incorporation of the drug into polymeric micelles. Jpn J Cancer Res 1999; 90:122-8.